



2022



Financed with restrictions

Orphan drugs are currently financed by the NHS



ODs with marketing authorisation and


financed by the NHS 2019 – 2022

ODs with NC and

financed by the NHS 2019 - 2022

% FINANCED


17



28 Under study or without funding request

60 Orphan drugs with National Code not financed by the NHS

32 Not financed by resolution



ODS WITH MARKETING AUTHORISATION WAITING FOR ARRIVAL TO SPAIN

23 DRUGS WITH MARKETING AUTHORISATION WITHOUT NATIONAL CODE

9%

% ODs WITH MARKETING AUTHORISATION

14%

Oncologicals

Others

15%


NO. OF UNFINANCED ODS PER NATIONAL CODE YEAR

16% 2022 % FROM THE YEAR OF THE MARKETING AUTHORISATION

2019

2020

2021 -




4%

13%



ADVANCED THERAPIES WITH ORPHAN DESIGNATION


13%



APPROVALS AND FINANCING

With National Code

Financed by the NHS





Spanish Agency for Medicines and Health Products (AEMPS) and the Ministry of Health.

twitter.com/aelmhu aelmhu.es

but was withdrawn in 2019.

Note: for the preparation of this report, it was not possible to consider drugs that are available in Spain under specific situations and special authorisations within the framework of **Royal Decree** 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data cannot be consulted in public sources.

The sources relied on for this report are the European Medicines Agency (EMA), the Community Register of orphan medicinal products, the

linkedin.com/company/aelmhu

2018

* Onivyde® is included in the recount of medicines financed by the NHS as of 31/12/2022. During December 2022, Onivyde® was reinstated in Nomenclátor. This product was financed in 2018,